Biggest News Aggregation in the World
📰 Ak 620 News

Ak 620 News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Ak 620. Real-time updates on events, politics, business and more.

Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the data from the pivotal Phase 3 SOLSTICE clinical trial of LIVTENCITY™ (maribavir, TAK-620) in post-transplant refractory† CMV infections with or without resistance‡ (R/R) were published in the journal of Clinical Infectious Diseases (CID).
United States Clin Virol Takeda Pharmaceuticals United States Inc International Report On Organ Donation Takeda Pharmaceutical Company Limited World Health Organization

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science